Atnahs Pharma firms €354 million term B at Euribor plus 500 bps

By Sara Rosenberg

New York, Sept. 26 – Atnahs Pharma (Antigua Bidco Ltd.) set pricing on its €354 million seven-year covenant-lite term loan B (B2//B+) at Euribor plus 500 basis points, the high end of the Euribor plus 475 bps to 500 bps talk, according to a market source.

The term loan still has a 0% floor and an original issue discount of 99.

Barclays and Credit Suisse are the global coordinators on the deal and mandated lead arrangers with HSBC and Jefferies. Barclays is the administrative agent.

Proceeds will be used to support Triton’s acquisition of the company and to pay related fees and expenses.

Atnahs is a U.K.-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.